NeurologyLive® Mind Moments® – Détails, épisodes et analyse

Détails du podcast

Informations techniques et générales issues du flux RSS du podcast.

NeurologyLive® Mind Moments®

NeurologyLive

Forme & Santé

Éducation

Sciences

Fréquence : 1 épisode/13j. Total Éps: 194

Mind Moments®, a podcast from NeurologyLive®, brings you exclusive interviews with experts in neurologic disorders.

Listen in to hear the latest clinical and research updates from major medical conferences, as well as insights on the management of complex disorders, including epilepsy, migraine, Alzheimer disease, stroke, multiple sclerosis, Parkinson disease, and more.

For more expert insight into neurology, visit NeurologyLive.com.

Lire plusRéduire

Site

RSS

Apple

Classements récents

Dernières positions dans les classements Apple Podcasts et Spotify.

Apple Podcasts

🇫🇷 France - medicine
17/08/2026
#93
🇫🇷 France - medicine
16/08/2026
#67
🇫🇷 France - medicine
15/08/2026
#39
🇫🇷 France - medicine
23/06/2025
#85
🇫🇷 France - medicine
22/06/2025
#59
🇫🇷 France - medicine
21/06/2025
#56

Spotify

Aucun classement récent disponible

Liens partagés entre épisodes et podcasts

Liens présents dans les descriptions d'épisodes et autres podcasts les utilisant également.

http://neurologylive.com/
181 partages
http://medicalworldnews.com
45 partages
http://medicalworldnews.com/
42 partages

https://www.linkedin.com/posts/alberto-espay-9a834758_a-visual-abstract-of-the-lecanemab-data-activity-7082979520554684416-Z1p4?utm_source=share&amp
1 partage

Qualité et score du flux RSS

Évaluation technique de la qualité et de la structure du flux RSS.

Qualité du flux RSS

À améliorer

Score global : 48%

Historique des publications

Répartition mensuelle des publications d'épisodes au fil des années.

Year

Derniers épisodes publiés

Liste des épisodes récents, avec titres, durées et descriptions.

172: Episode 172: Spinal Muscular Atrophy Awareness Month: Why Multidisciplinary Care Matters

Épisode 172

vendredi 7 août 2026 • Durée 15:19

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In episode 172, “Spinal Muscular Atrophy Awareness Month: Why Multidisciplinary Care Matters,” Sandeep Rana, MD, a neurologist specializing in neuromuscular disorders at Allegheny Health Network, discussed the multidisciplinary care model for spinal muscular atrophy (SMA) implemented in his center, in honor of SMA Awareness Month. He described a clinic structure that includes physical and occupational therapists, respiratory therapists, nutritionists, speech therapists, social workers, and collaboration with pulmonologists experienced in neuromuscular disease.

Rana also outlined how the advent of disease-modifying therapies has transformed SMA from a largely fatal illness into a more manageable condition. He highlighted key advancements in therapeutics that have shifted priorities toward long-term wellness, including weight management, physical fitness, and emotional health. He noted persistent challenges in organizing and sustaining a specialized multidisciplinary team. Finally, he emphasized the importance of clinician awareness, early identification, and timely referral to tertiary centers, particularly as additional therapies may become available.

Looking for more neuromuscular disorder discussions? Check out the NeurologyLive® Neuromuscular Disorders clinical focus page.

Episode Breakdown:

1:25 – Professional background and clinic overview
2:55 – What an effective multidisciplinary SMA care team looks like
5:12 – How disease-modifying therapies have changed SMA care
6:28 – Neurology News Minute
9:27 – Organizational and procedural challenges in coordinating care
11:52 – Why raising awareness about SMA is important & advice to clinicians
13:45 – Key message about SMA today

The stories featured in this week’s Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

Lire plusRéduire

Special Episode: Na Tosha, Gatson, MD, PhD, on Newly Launched Neuro-Oncology Column

jeudi 30 juillet 2026 • Durée 20:11

In this special edition of Mind Moments, Na Tosha Gatson, MD, PhD, senior medical director of neuro-oncology and director of the Center for Neuro-Oncology at Indiana University School of Medicine, joins the podcast to discuss her career journey, philosophy of patient care, and the launch of The G.L.O.B., a new recurring NeurologyLive column dedicated to advancing health literacy in neuro-oncology. Drawing on decades of experience in neuro-oncology, clinical leadership, and mentorship, Gatson shares the motivation behind creating a platform that transforms complex oncologic concepts into practical, accessible knowledge for clinicians, patients, and caregivers alike.

The conversation explores the inspiration behind The G.L.O.B., the importance of effective medical communication, lessons learned throughout Gatson's career, and the role of health literacy, shared decision-making, and health equity in modern neurologic care. She also discusses her vision for the future of the column and why improving patient understanding should remain central to both clinical practice and research.

Episode Breakdown:

1:10 – Journey into neuro-oncology and career-defining experiences
4:50 – Mission and philosophy behind The G.L.O.B.
7:10 – Key themes readers can expect from the column
9:45 – Career lessons that shaped Dr. Gatson's clinical practice
16:30 – Vision for The G.L.O.B. and improving healthy literacy

163: The Clinical Reality of Seronegative Myasthenia Gravis

Épisode 163

vendredi 3 avril 2026 • Durée 16:56

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this Mind Moments episode, Sarah Hoffmann, MD, PhD, senior neurologist at Charité – University Medicine Berlin, provides clinical insight into the evolving and often challenging landscape of seronegative generalized myasthenia gravis (gMG). Drawing from both clinical experience and research, Hoffmann discusses how seronegative MG is defined in the absence of detectable antibodies and why it represents a heterogeneous and often underrecognized subgroup of patients. The conversation explores key diagnostic challenges, particularly in patients with limb-predominant symptoms, where differentiation from other neuromuscular or functional disorders can be difficult. Hoffmann also reviews current treatment approaches, noting that while standard therapies mirror antibody-positive MG, access to targeted treatments remains limited. Additional discussion focuses on the barriers to advancing clinical trials in this population, the need for reliable biomarkers to better stratify patients, and the importance of continually reassessing diagnosis in nonresponders to avoid both undertreatment and overtreatment.

Looking for more neuromuscular discussion? Check out the NeurologyLive® Neuromuscular clinical focus page.

Episode Breakdown:

1:15 – Defining seronegative MG and estimating prevalence within overall patient population
2:15 – Diagnostic challenges and distinguishing seronegative MG from mimics and functional disorders
5:35 – Role and limitations of antibody testing, electrophysiology, and pharmacologic response
6:50 – Neurology News Network
9:05 – Current treatment strategies and variability in access to targeted therapies
11:55 – Barriers to clinical trials and need for improved patient stratification methods

Special Episode: Tofersen Approved for SOD1 ALS

mardi 25 avril 2023 • Durée 12:12

Welcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.

In this episode, we're covering the recent approval of tofersen (Qalsody; Biogen/Ionis) in SOD1 mutation-mediated amyotrophic lateral sclerosis (ALS). Offering commentary is Angela Genge, MD, FRCPC, the director of the ALS Centre of Excellence for Research and Patient Care at McGill University, and an executive at the Clinical Research Unit at The Neuro (Montreal Neurological Institute-Hospital). Tofersen is an antisense oligonucleotide, and its new drug application (NDA) was supported by data from a phase 1 study of healthy volunteers, a phase 1/2 dose-ascending study, the pivotal phase 3 VALOR study (NCT02623699), and its open-label extension.

For more of NeurologyLive®'s coverage of tofersen's approval, head here: FDA Approves Tofersen as First SOD1-ALS Treatment
Episode Breakdown:

0:30 – Tofersen (Qalsody; Biogen/Ionis) approved for SOD1-ALS
1:35 – Angela Genge, MD, FRCPC, on the approval
3:05 – The implications of targeting a root cause of ALS
5:00 – Data from the supporting VALOR study
5:55 – Genge on the context around the trial data
7:35 – Questions about access to tofersen amid accelerated approval

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

REFERENCES1. FDA approves treatment of amyotrophic lateral sclerosis associated with a mutation in the SOD1 gene. News release. FDA. April 25, 2023. Accessed April 25, 2023. 2. Miller TM, Cudkowicz ME, Genge A, et al. Trial of antisense oligonucleotide tofersen for SOD1 ALS. . 2022;387:1099-1110. doi:10.1056/NEJMoa2204705.

87: Severe Multiple Sclerosis and the CASA-MS Study

Épisode 87

vendredi 21 avril 2023 • Durée 29:49

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with Robert Zivadinov, MD, PhD, director of the Buffalo Neuroimaging Analysis Center, and a professor of neurology and biomedical informatics at the Jacobs School of Medicine & Biomedical Sciences at the University at Buffalo. He discussed the recent CASA-MS study that he and colleagues conducted into a subgroup of patients with multiple sclerosis (MS) who develop rapid and progressive disability at a relatively young age, which he presented earlier this year at the 2023 Americas Committee for Treatment and Research in MS Forum, and the critical effectively need to treat this group of patients. The study was carried out at The Boston Home, a specialized residential facility for individuals with advanced progressive neurological disorders, in Dorchester, Massachusetts, and at the University at Buffalo, in New York.

Looking for more Multiple Sclerosis discussion? Check out the NeurologyLive® multiple sclerosis clinical focus page.

Episode Breakdown:

1:10 – Background on the CASA-MS study subpopulation
3:45 – Topline results of the study
6:05 – The need for further clarification in MS populations
7:10 – The utility of biomarkers such as GFAP
12:15 – Further assessment plans for the CASA-MS cohort
14:15 – Neurology News Minute
18:35 – Access to the tools to characterize progressive MS
21:30 – The potential with portable MRI and artificial intelligence
25:25 – Unmet needs in progressive MS

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Thanks for listening to the ® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit .REFERENCE1. Zivadinov R, Jakimovski D, Burnham A, et al. Comprehensive Assessment of Severely Affected Multiple Sclerosis (CASA-MS) Study. Presented at: ACTRIMS Forum; February 25-28, 2023; San Diego, CA. P430.

86: Pimavanserin and Atypical Antipsychotics to Treat Parkinson Disease Psychosis

Épisode 86

vendredi 7 avril 2023 • Durée 21:41

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with Dilesh Doshi, PharmD, vice president of Health Economic and Outcomes Research at Acadia Pharmaceuticals. He spoke on the advantages and benefits of pimavanserin (Nuplazid; Acadia), the only FDA-approved therapy to treat Parkinson disease psychosis. Additionally, he discussed recent data that compared efficacy and safety of other off-label therapies such as clozapine and quetiapine.

Looking for more Parkinson disease discussion? Check out the NeurologyLive® movement disorder clinical focus page.

Episode Breakdown:

1:10 – Mechanistic differences between pimavanserin and other atypical antipsychotics
3:00 – Understanding drug-to-drug interactions for PDP
5:05 – Decision making with quetiapine and negative cognitive effects
7:10 – Improved use of pimavanserin since approval
9:00 – Neurology News Minute
11:40 – Potential predictors of mortality in Parkinson disease psychosis
15:20 – Possibility of preventing PD psychosis
17:20 – Future research on identifying subgroups of responders to treatment

This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com.

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Thanks for listening to the ® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit .

85: Impact of Narcolepsy on Social Relationship Health in Adolescents

Épisode 85

vendredi 24 mars 2023 • Durée 14:30

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with Eric Zhou, PhD, assistant professor of pediatrics at Harvard Medical School. He spoke on a recently conducted study assessing the link between narcolepsy in adolescents and social relationship health. Specifically, he talked about how the sleep disorder impacts mood, physical activities, driving, and other long-term health outcomes, as well as ways we can help adolescents with narcolepsy at the earliest stages.

Looking for more narcolepsy discussion? Check out the NeurologyLive® narcolepsy clinical focus page.

Episode Breakdown:

1:20 – Identified links between narcolepsy and social relationships
3:05 – Long-term impacts of affected mood, physical activities, and driving
4:15 – Current assessment of narcolepsy in adolescents
5:30 – Neurology News Minute
8:05 – Attempts to prevent narcolepsy at earliest stages
9:15 – Implementing programs in school to help adolescents with narcolepsy
11:20 – Future research on narcolepsy in younger populations

Special Episode: Trofinetide Approved for Rett Syndrome

lundi 13 mars 2023 • Durée 11:42

Welcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.

In this episode, we're covering the recent approval of trofinetide (Daybue; Acadia) in Rett syndrome. Offering commentary is Jeffrey L. Neul, MD, PhD, the Annette Schaffer Eskind Chair and director of the Vanderbilt Kennedy Center, and professor of pediatrics at Vanderbilt University Medical Center, and the lead investigator on the phase 3 study of the drug, called LAVENDER (NCT04181723). Trofinetide is a synthetic analog of the amino‐terminal tripeptide of IGF-1, and is now the first treatment approval for Rett syndrome, marking a milestone in the field of developmental disorder care.

For more of NeurologyLive®'s coverage of trofinetide's approval, head here: FDA Approves Acadia's Trofinetide for Rett Syndrome
Episode Breakdown:

0:30 – Trofinetide (Daybue; Acadia) approved for Rett syndrome
1:30 – Jeffrey L. Neul, MD, PhD, on the approval
4:10 – Prevalence of Rett syndrome and the impact on research
5:40 – Supporting data from the phase 3 LAVENDER study
7:20 – Safety data from the clinical development and managment of common adverse events
8:45 – Closing thoughts

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

REFERENCES
1. Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older News Release. Acadia Pharmaceuticals. March 10, 2023. Accessed March 13, 2023. 2. Neul JL. Rett Syndrome. National Organization for Rare Diseases. Updated December 17, 2019. Accessed March 13, 2023.

84: Parkinson Disease Education for Community Providers

Épisode 84

vendredi 10 mars 2023 • Durée 30:42

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with Elizabeth “Eli” Pollard, vice president & chief education and training officer at the Parkinson's Foundation, and the executive director of the World Parkinson Coalition. She spoke about the foundation's ongoing efforts in providing education about Parkison disease (PD), the challenges of managing a growing population of patients, the need for community physicians and specialists to work in unison, and more.

>>Click here to access the Parkinson Foundation's educational series.

Looking for more Parkinson disease discussion? Check out the NeurologyLive® PD disease spotlight page.

Episode Breakdown:

1:20 – The need for education across the PD care paradigm
4:40 – An overview of the 6-part educational series
6:10 – The inclusion of specialties such as dentistry in the care of PD
9:40 – Using training to overcome gaps in multidisciplinary care
13:05 – Challenges in educating a large population of providers
16:55 – Neurology News Minute
19:00 – Improving access to clinical education

83: The ARISE Study and Using DMTs in RIS

Épisode 83

vendredi 24 février 2023 • Durée 20:51

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with Darin Okuda, MD, director of Neuroinnovation and Multiple Sclerosis & Neuroimmunology Imaging Program at UT Southwestern Medical Center. He spoke about the phase 2 ARISE study assessing dimethyl fumarate (Tecfidera; Biogen) in patients with radiologically isolated syndrome, the significance of the findings, next steps in validating this therapy, and more.

Looking for more multiple sclerosis discussion? Check out the NeurologyLive® multiple sclerosis clinical focus page.

Episode Breakdown:

1:20 – Overview of ARISE and conduct of study
4:20 – Potential subgroup responders to dimethyl fumarate
8:10 – Efforts to improve the detection of radiologically isolated syndrome
10:05 – Neurology News Minute
11:55 – Next steps of research following ARISE
16:50 – Closing thoughts on significance of the study

CNM-Au8 Shows Positive Findings on MS-Related Biomarkers of Whole Brain, White Matter

Thanks for listening to the ® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit .REFERENCEOkuda DT, Kantarci O, Lebrun-Frenay C, et al. Dimethyl fumarate delays multiple sclerosis radiologically isolated syndrome. 2023;93(3):604-614. doi:10.1002/ana.26555

Podcasts Similaires Basées sur le Contenu

Découvrez des podcasts liées à NeurologyLive® Mind Moments®. Explorez des podcasts avec des thèmes, sujets, et formats similaires. Ces similarités sont calculées grâce à des données tangibles, pas d'extrapolations !

Il n'y a pas de contenu associé à ce podcast.

À propos Méthodologie Contact Me soutenir Politique de confidentialité

NeurologyLive® Mind Moments® – Détails, épisodes et analyse

Détails du podcast

Classements récents

Apple Podcasts

Spotify

Liens partagés entre épisodes et podcasts

Other99+

LinkedIn1

Qualité et score du flux RSS

Historique des publications

Derniers épisodes publiés

Podcasts et contenus similaires

Podcasts Similaires Basées sur le Contenu

Apple Podcasts

Spotify

Podcasts Similaires Basées sur le Contenu

Other99+

LinkedIn1